Pe-22-28 Vial Size — Dosing and Storage Specs

Most researchers ordering PE-22-28 for the first time focus on purity percentages and pricing—then realize too late that the pe-22-28 vial size they selected doesn't align with their dosing protocol. A 5mg vial reconstituted with 2ml bacteriostatic water gives you a completely different concentration per unit volume than a 10mg vial in the same volume, and that difference determines whether your micro-dosing schedule is practical or mathematically frustrating.

We've guided hundreds of research teams through peptide procurement decisions. The gap between selecting the right vial format and the wrong one comes down to three factors most supplier pages never mention: reconstitution math, refrigerated shelf life after mixing, and whether your dosing schedule creates compound waste.

What is the standard pe-22-28 vial size available for research?

PE-22-28 vial size typically ranges from 5mg to 10mg of lyophilized peptide per vial, with 5mg being the most common format for initial research protocols. Reconstitution with 1–2ml bacteriostatic water produces concentrations between 2.5mg/ml and 5mg/ml, allowing precise micro-dosing with standard insulin syringes. The vial format you select should match your planned administration frequency and total study duration to minimize waste from exceeding the 28-day post-reconstitution stability window.

Yes, PE-22-28 is available in multiple vial sizes—but the concentration per milliliter after reconstitution is what actually determines usability in your protocol. A 10mg vial isn't automatically better than a 5mg vial if your dosing schedule only requires 500mcg per administration twice weekly. The larger format forces you to reconstitute more peptide than you'll use within the bacteriostatic water's 28-day sterility window, turning the second half of the vial into expensive waste. This article covers how pe-22-28 vial size affects reconstitution ratios, what dosing math looks like across common research schedules, and which vial format aligns with different study designs without creating avoidable compound loss.

PE-22-28 Vial Size and Reconstitution Mathematics

The pe-22-28 vial size you select directly determines your reconstitution ratio, which is the relationship between total peptide mass (in milligrams) and the volume of bacteriostatic water you add (in milliliters). This ratio produces your final concentration—expressed as milligrams per milliliter (mg/ml)—which then dictates how many units you draw on an insulin syringe to achieve your target dose.

A 5mg vial of PE-22-28 reconstituted with 2ml of bacteriostatic water produces a concentration of 2.5mg/ml. If your research protocol calls for a 500mcg (0.5mg) dose, you would draw 0.2ml—or 20 units on a standard U-100 insulin syringe. The same 500mcg dose from a 10mg vial reconstituted with 2ml bacteriostatic water (5mg/ml concentration) requires only 0.1ml, or 10 units. The dosing volume changes, but the peptide mass delivered remains identical.

Why does this matter? Smaller draw volumes (under 10 units) become increasingly difficult to measure accurately with standard syringes, introducing variability into your dosing schedule. Larger draw volumes (above 50 units per dose) deplete your vial faster, requiring more frequent reconstitution cycles. The ideal pe-22-28 vial size produces a concentration that keeps your per-dose draw volume between 10 and 40 units—precise enough to measure reliably, conservative enough to extend vial lifespan.

Consider a research protocol requiring 250mcg of PE-22-28 administered three times per week over eight weeks. That's 24 total doses requiring 6mg of total peptide. A single 10mg vial provides enough compound with 4mg remaining, but once reconstituted, bacteriostatic water maintains sterility for only 28 days. If your 24 doses span 56 days (eight weeks), you'll need to reconstitute a second vial halfway through—wasting the 4mg remaining in the first vial and the untouched portion of the second. Two 5mg vials aligned to your study timeline eliminate that waste entirely.

Reconstitution precision also depends on your bacteriostatic water volume. Adding exactly 2.00ml of water to a 5mg vial is straightforward with a 3ml syringe, but attempting to add 1.5ml or 2.3ml introduces measurement error that compounds across every dose you draw. Round-number reconstitution volumes—1ml, 2ml, or 5ml—reduce human error and make concentration calculations simpler during active research.

Our team has reviewed reconstitution protocols across hundreds of peptide studies. The researchers who report the highest dosing consistency are those who select vial sizes that produce whole-number or simple-decimal concentrations after reconstitution with standard bacteriostatic water volumes. A 5mg vial with 2ml water (2.5mg/ml) or a 10mg vial with 2ml water (5mg/ml) both meet this standard. A 7mg vial would require 2.8ml water to produce 2.5mg/ml—a volume that's awkward to measure accurately and introduces unnecessary complexity.

Storage Stability and the 28-Day Reconstitution Window

PE-22-28 in lyophilized (freeze-dried) powder form remains stable for 24–36 months when stored at -20°C, but the moment you reconstitute it with bacteriostatic water, the stability clock resets to 28 days under refrigeration at 2–8°C. This is not a manufacturer-imposed expiration date—it's the sterility guarantee window for bacteriostatic water containing 0.9% benzyl alcohol as a preservative. Beyond 28 days, bacterial contamination risk increases even if the peptide itself hasn't degraded.

The pe-22-28 vial size you choose must align with this 28-day window. If your research protocol requires only 3mg of PE-22-28 over four weeks, a 5mg vial allows you to complete the study with one reconstitution cycle and minimal waste. A 10mg vial forces you to either (1) discard 7mg of unused peptide after 28 days, or (2) risk using peptide beyond the bacteriostatic water's sterility guarantee.

Temperature excursions compound this issue. Every time a reconstituted vial sits at room temperature—during dose preparation, accidental countertop storage, or transport without cold packs—the peptide structure begins to denature. PE-22-28 contains a specific amino acid sequence that maintains bioactivity only when the tertiary protein structure remains intact. Heat, even moderate ambient temperatures of 20–25°C sustained over hours, disrupts hydrogen bonds within the peptide chain. The result isn't visibly obvious—the solution remains clear—but the compound's effectiveness in your research model diminishes.

One common mistake: researchers calculate total peptide needed for a study, purchase the corresponding vial size, then realize their dosing schedule spans longer than 28 days. A 12-week study requiring 500mcg twice weekly totals 12mg of PE-22-28. Ordering a single 15mg vial seems efficient, but you'll need to reconstitute it, use what you can within 28 days, then discard the remainder and reconstitute a second vial mid-study. Two separate 10mg vials, each reconstituted at the appropriate study phase, would have been more practical.

The solution is dose-phase planning. Break your research timeline into 28-day blocks, calculate the peptide mass required per block, then select vial sizes that match each block with 10–20% overhead. For an eight-week study, plan two reconstitution phases: weeks 1–4 and weeks 5–8. If each phase requires 4mg, order two 5mg vials rather than one 10mg vial. The total peptide mass is the same, but the format aligns with the bacteriostatic water stability window.

Peptide storage isn't negotiable. Unreconstituted PE-22-28 must remain at -20°C—not in a frost-free freezer, which cycles temperatures during defrost phases. Once reconstituted, refrigerate at 2–8°C immediately. A medication cooler rated for this range is essential if your lab lacks a dedicated peptide refrigerator. Purpose-built coolers like FRIO wallets maintain 2–8°C using evaporative cooling without requiring ice or electricity, making them reliable for both storage and transport during multi-site studies.

Dosing Precision Across Common Research Protocols

The pe-22-28 vial size that works for a single-dose pilot study fails entirely in a sustained 12-week protocol, and the format ideal for high-frequency micro-dosing becomes impractical for weekly administration schedules. Matching vial size to your specific dosing cadence eliminates waste and maintains measurement precision.

Consider three common PE-22-28 research models. Model A administers 1mg once weekly for cognitive enhancement studies—12mg total over 12 weeks. Model B uses 250mcg three times per week for neuroprotection trials—9mg total over 12 weeks. Model C employs 100mcg daily for neurogenesis observation—8.4mg total over 12 weeks. All three require similar total peptide mass, but the ideal vial size differs across each.

Model A benefits from a 10mg vial reconstituted with 2ml bacteriostatic water, producing 5mg/ml concentration. Each 1mg dose requires a 0.2ml (20-unit) draw—easy to measure accurately and large enough to avoid the precision issues of sub-10-unit draws. The vial supports 10 total doses, covering the first 10 weeks within one reconstitution cycle. A second 5mg vial reconstituted in week 9 or 10 covers weeks 11–12 without exceeding the 28-day sterility window.

Model B works better with 5mg vials. At 250mcg three times weekly, you'll administer 750mcg per week—3mg every four weeks. A 5mg vial reconstituted with 2ml water (2.5mg/ml) allows a 0.1ml draw per 250mcg dose. One vial covers nearly seven weeks of dosing, but because the 28-day bacteriostatic limit arrives first, you'll reconstitute a second vial at week 4. Three 5mg vials staggered across the 12-week study provide full coverage with minimal waste. A 10mg vial would force you to discard unused peptide every 28 days despite having compound remaining.

Model C, with 100mcg daily dosing, requires the smallest draw volumes—0.04ml (4 units) per dose if using a 5mg vial at 2.5mg/ml concentration. This approaches the lower limit of reliable measurement with standard insulin syringes. A better approach: use a 10mg vial reconstituted with 5ml bacteriostatic water, producing 2mg/ml concentration. Now each 100mcg dose requires 0.05ml (5 units)—still small, but more reliably measurable. Daily dosing consumes 700mcg weekly, so one 10mg vial supports roughly 14 days. You'll reconstitute a new vial every two weeks, staying well within the 28-day sterility window and maintaining dose accuracy.

Draw volume precision matters because insulin syringes, the standard tool for peptide administration in research, are calibrated in units where 1 unit equals 0.01ml. A 4-unit draw (0.04ml) leaves significant room for human error—the meniscus reading, plunger pressure, and air bubble presence all introduce variability. A 10-unit draw (0.1ml) or larger minimizes these factors. If your reconstitution math produces per-dose volumes under 5 units, consider increasing your bacteriostatic water volume to dilute the concentration further, raising draw volume into the 10–20 unit range where measurement reliability improves.

In our experience working with research teams using PE-22-28 across neurogenesis and cognitive longevity studies, the protocols that maintain the tightest dose consistency are those where per-administration draw volumes fall between 10 and 30 units. Below 10 units, measurement error increases. Above 50 units per dose, vials deplete faster than anticipated, and researchers find themselves reconstituting mid-study phase more frequently than planned. The pe-22-28 vial size and reconstitution volume should be reverse-engineered from this target draw range, not selected based on total peptide mass alone.

Pe-22-28 Vial Size: Format Comparison

Before selecting a vial size, compare how different formats perform across reconstitution math, dosing precision, and study duration alignment. The table below shows four common pe-22-28 vial size options with standard reconstitution volumes and the resulting concentrations.

The 5mg format remains the most versatile choice for single-investigator studies or initial protocol development. It allows one full reconstitution cycle to align with typical 4-week exploratory phases without forcing premature vial depletion or excess waste. Researchers using PE-22-28 for cognitive or neurogenic observation over 6–8 weeks typically order two 5mg vials, reconstituting the second at the start of week 5.

What If: Pe-22-28 Vial Size Scenarios

What If I Ordered a 10mg Vial But My Study Only Needs 4mg Over Four Weeks?

Reconstitute only what you'll use within 28 days, but you cannot partially reconstitute a lyophilized vial—once you add bacteriostatic water, the entire peptide mass dissolves. The unused 6mg will exceed the sterility window before you can use it. The correct approach for future orders: purchase two 5mg vials and reconstitute only the first for the initial study phase. The second vial remains stable in lyophilized form at -20°C until needed. For the current scenario, if budget allows, reserve the reconstituted 10mg vial for an extended study or additional subjects to prevent compound waste.

What If My Reconstituted PE-22-28 Was Left at Room Temperature for Six Hours?

Peptide denaturation occurs progressively at temperatures above 8°C, but six hours at 20–25°C doesn't render PE-22-28 completely inactive—it degrades partial bioactivity. The exact percentage loss depends on ambient temperature and whether the vial was exposed to light. If this was a single incident, refrigerate the vial immediately and continue your study, but note the temperature excursion in your records as a potential confounding variable. If your research model is sensitive to dose consistency (neurogenesis studies, receptor binding assays), consider that vial compromised and reconstitute a replacement. Heat exposure is cumulative—one six-hour event may be recoverable, but repeated excursions degrade the peptide beyond usability.

What If I Need to Dose 100mcg Daily But My 5mg Vial Produces Draw Volumes Under 5 Units?

Increase your reconstitution volume to dilute concentration and raise draw volume into a measurable range. A 5mg vial reconstituted with 5ml bacteriostatic water produces 1mg/ml concentration, meaning each 100mcg dose requires 0.1ml or 10 units—double the precision of a 5-unit draw. The trade-off: your vial now contains 5ml total volume instead of 2ml, depleting faster per dose and requiring refrigerator space for a larger vial. This is the correct approach for micro-dosing protocols where measurement accuracy outweighs vial compactness.

What If My Study Timeline is 10 Weeks But I Want to Minimize Reconstitution Cycles?

You cannot extend the 28-day bacteriostatic water sterility window, so any study longer than four weeks requires at least two reconstitution cycles. The best strategy: calculate your peptide needs for weeks 1–4 and weeks 5–10 separately, then order vial sizes that align with each phase. If weeks 1–4 require 3mg and weeks 5–10 require 5mg, order one 5mg vial for phase one and one 10mg vial for phase two. Reconstitute the second vial at the start of week 5. Attempting to reduce reconstitution cycles by using oversized vials just creates waste—you'll discard unused peptide at day 28 regardless of how much remains.

The Practical Truth About Pe-22-28 Vial Size Selection

Here's the honest answer: most researchers overthink vial size by focusing on total peptide mass instead of study phase alignment. The pe-22-28 vial size that matters isn't the one with the most milligrams—it's the one that matches your 28-day reconstitution windows without leaving unused compound in the refrigerator on day 29.

The 5mg vial is the default correct choice for 90% of initial PE-22-28 research. It provides enough peptide for meaningful observation periods, reconstitutes into concentrations that keep draw volumes measurable, and aligns with the bacteriostatic water sterility timeline without forcing waste. Larger vials only make sense when you have confirmed dosing schedules, multiple study phases planned in advance, or institutional cold storage that supports strict 28-day cycle discipline. The researchers who report the lowest compound waste and highest dosing consistency are those who buy smaller vials more frequently rather than larger vials they can't fully utilize within the sterility window.

If your study is exploratory, your dosing protocol is still being refined, or this is your first time working with PE-22-28, order 5mg vials. If your research model is established, your timeline spans 12+ weeks, and you've calculated exact peptide needs across multiple 28-day phases, then 10mg vials with staggered reconstitution become practical. The vial size itself doesn't determine research success—matching the format to your actual usage pattern does.

Peptide procurement is one of the few research decisions where smaller, more frequent orders outperform bulk purchasing. Unreconstituted lyophilized PE-22-28 remains stable for years at -20°C, so there's no penalty for ordering the next vial when you need it rather than stockpiling formats that don't align with your study cadence. Real Peptides maintains consistent stock of both 5mg and 10mg PE-22-28 formats, and our small-batch synthesis ensures every vial meets the same purity standard regardless of size. Researchers using PE 22 28 across extended cognitive and neurogenic studies consistently choose vial sizes that fit their phase timelines rather than their total study mass—that's the pattern that eliminates waste and maintains protocol consistency.

If the pe-22-28 vial size you're considering would leave more than 20% unused compound at the end of a 28-day cycle, choose the next smaller format and plan a second reconstitution instead. The cost difference between vial sizes is negligible compared to the peptide you'll discard if you over-purchase.